PMID- 37226045
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230616
IS  - 2578-5745 (Electronic)
IS  - 2578-5745 (Linking)
VI  - 5
IP  - 6
DP  - 2023 Jun
TI  - Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During 
      the First Year After Initiating Oral Corticosteroids: A Retrospective US Database 
      Study.
PG  - 318-328
LID - 10.1002/acr2.11550 [doi]
AB  - OBJECTIVE: To characterize health care resource utilization (HCRU), health care 
      costs, and adverse events (AEs) among patients with systemic lupus erythematosus 
      (SLE) initiating oral corticosteroids (OCS) versus patients without OCS use. 
      METHODS: In this retrospective cohort study (GSK Study 213061), eligible patients 
      (aged >/=5 years at first OCS claim) with SLE from the IQVIA Real-World Data 
      Adjudicated Claims-US database (January 2006 to July 2019) had continuous 
      enrollment during the 6-month preindex (baseline) and 12-month postindex 
      (observation) periods and one or more inpatient or emergency department SLE 
      diagnosis codes or two or more outpatient SLE diagnosis codes during baseline. 
      The "OCS-initiator cohort" comprised patients with one or more OCS pharmacy 
      claims during the study period and no evidence of preindex OCS use and was 
      classified into three exposure categories based on the number of 6-month periods 
      of more than 5 mg/day of OCS use (0, 1, 2). The "no-OCS-use cohort" comprised 
      patients without OCS claims, although patients may have received OCS prior to the 
      study period. Clinical and economic outcomes were reported over the observation 
      period. RESULTS: Adjusted health care costs differed significantly ($6542 [95% 
      confidence interval (CI): $5761-$7368], $19,149 [95% CI: $16,954-$21,471], 
      $28,985 [95% CI: $25,546-$32,885]). HCRU incidence rates were significantly 
      greater for all OCS-initiator exposure categories (n = 16,216) versus the 
      no-OCS-use cohort (n = 11,137; adjusted incidence rate ratios [95% CI]: 1.22 
      [1.19-1.24], 1.39 [1.34-1.43], 1.66 [1.60-1.73]). OCS-related AEs were 
      experienced by 67.1% to 74.1% of patients with OCS initiation, most commonly 
      affecting the immune system. CONCLUSION: Within 12 months of OCS initiation, 
      patients with SLE experienced substantial clinical and economic burden, which may 
      imply a need to minimize OCS use.
CI  - (c) 2023 GSK and The Authors. ACR Open Rheumatology published by Wiley Periodicals 
      LLC on behalf of American College of Rheumatology.
FAU - DerSarkissian, Maral
AU  - DerSarkissian M
AD  - Maral DerSarkissian, PhD, Yuqian M. Gu, MS (current address: Kaiser Permanente, 
      Pasadena, CA, United States), Mei Sheng Duh, MPH, ScD, John Benson, MS, Jensen 
      Vu, BA (current address: Republic, New York, NY, United States, and 
      VietChallenge, Boston, MA, United States), Min-Jung Wang, ScD,MS (current 
      address: Amgen Inc., Thousand Oaks, CA, United States): Analysis Group, Inc., 
      Boston, Massachusetts, United States.
FAU - Gu, Yuqian M
AU  - Gu YM
AD  - Maral DerSarkissian, PhD, Yuqian M. Gu, MS (current address: Kaiser Permanente, 
      Pasadena, CA, United States), Mei Sheng Duh, MPH, ScD, John Benson, MS, Jensen 
      Vu, BA (current address: Republic, New York, NY, United States, and 
      VietChallenge, Boston, MA, United States), Min-Jung Wang, ScD,MS (current 
      address: Amgen Inc., Thousand Oaks, CA, United States): Analysis Group, Inc., 
      Boston, Massachusetts, United States.
FAU - Duh, Mei Sheng
AU  - Duh MS
AD  - Maral DerSarkissian, PhD, Yuqian M. Gu, MS (current address: Kaiser Permanente, 
      Pasadena, CA, United States), Mei Sheng Duh, MPH, ScD, John Benson, MS, Jensen 
      Vu, BA (current address: Republic, New York, NY, United States, and 
      VietChallenge, Boston, MA, United States), Min-Jung Wang, ScD,MS (current 
      address: Amgen Inc., Thousand Oaks, CA, United States): Analysis Group, Inc., 
      Boston, Massachusetts, United States.
FAU - Benson, John
AU  - Benson J
AD  - Maral DerSarkissian, PhD, Yuqian M. Gu, MS (current address: Kaiser Permanente, 
      Pasadena, CA, United States), Mei Sheng Duh, MPH, ScD, John Benson, MS, Jensen 
      Vu, BA (current address: Republic, New York, NY, United States, and 
      VietChallenge, Boston, MA, United States), Min-Jung Wang, ScD,MS (current 
      address: Amgen Inc., Thousand Oaks, CA, United States): Analysis Group, Inc., 
      Boston, Massachusetts, United States.
FAU - Huang, Shirley P
AU  - Huang SP
AUID- ORCID: 0000-0001-5849-3731
AD  - Shirley P. Huang, PharmD, MS (current address: Seagen Inc., Bothwell, WA, United 
      States), Carlyne Averell, MS, SM (no current affiliation), Christopher F. Bell, 
      PharmD, Research Triangle Park, North Carolina, United States.
FAU - Averell, Carlyne
AU  - Averell C
AD  - Shirley P. Huang, PharmD, MS (current address: Seagen Inc., Bothwell, WA, United 
      States), Carlyne Averell, MS, SM (no current affiliation), Christopher F. Bell, 
      PharmD, Research Triangle Park, North Carolina, United States.
FAU - Vu, Jensen
AU  - Vu J
AD  - Maral DerSarkissian, PhD, Yuqian M. Gu, MS (current address: Kaiser Permanente, 
      Pasadena, CA, United States), Mei Sheng Duh, MPH, ScD, John Benson, MS, Jensen 
      Vu, BA (current address: Republic, New York, NY, United States, and 
      VietChallenge, Boston, MA, United States), Min-Jung Wang, ScD,MS (current 
      address: Amgen Inc., Thousand Oaks, CA, United States): Analysis Group, Inc., 
      Boston, Massachusetts, United States.
FAU - Wang, Min-Jung
AU  - Wang MJ
AD  - Maral DerSarkissian, PhD, Yuqian M. Gu, MS (current address: Kaiser Permanente, 
      Pasadena, CA, United States), Mei Sheng Duh, MPH, ScD, John Benson, MS, Jensen 
      Vu, BA (current address: Republic, New York, NY, United States, and 
      VietChallenge, Boston, MA, United States), Min-Jung Wang, ScD,MS (current 
      address: Amgen Inc., Thousand Oaks, CA, United States): Analysis Group, Inc., 
      Boston, Massachusetts, United States.
FAU - Bell, Christopher F
AU  - Bell CF
AUID- ORCID: 0000-0001-6413-2537
AD  - Shirley P. Huang, PharmD, MS (current address: Seagen Inc., Bothwell, WA, United 
      States), Carlyne Averell, MS, SM (no current affiliation), Christopher F. Bell, 
      PharmD, Research Triangle Park, North Carolina, United States.
LA  - eng
GR  - GSK/
PT  - Journal Article
DEP - 20230524
PL  - United States
TA  - ACR Open Rheumatol
JT  - ACR open rheumatology
JID - 101740025
PMC - PMC10267805
EDAT- 2023/05/25 01:07
MHDA- 2023/05/25 01:08
PMCR- 2023/05/24
CRDT- 2023/05/24 23:35
PHST- 2023/04/11 00:00 [revised]
PHST- 2022/11/16 00:00 [received]
PHST- 2023/04/17 00:00 [accepted]
PHST- 2023/05/25 01:08 [medline]
PHST- 2023/05/25 01:07 [pubmed]
PHST- 2023/05/24 23:35 [entrez]
PHST- 2023/05/24 00:00 [pmc-release]
AID - ACR211550 [pii]
AID - 10.1002/acr2.11550 [doi]
PST - ppublish
SO  - ACR Open Rheumatol. 2023 Jun;5(6):318-328. doi: 10.1002/acr2.11550. Epub 2023 May 
      24.